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Abstract
Human lymphatic filariasis is a major tropical disease transmitted through mosquito vectors which take up microfilarial
larvae from the blood of infected subjects. Microfilariae are produced by long-lived adult parasites, which also release a
suite of excretory-secretory products that have recently been subject to in-depth proteomic analysis. Surprisingly, the most
abundant secreted protein of adult Brugia malayi is triose phosphate isomerase (TPI), a glycolytic enzyme usually associated
with the cytosol. We now show that while TPI is a prominent target of the antibody response to infection, there is little
antibody-mediated inhibition of catalytic activity by polyclonal sera. We generated a panel of twenty-three anti-TPI
monoclonal antibodies and found only two were able to block TPI enzymatic activity. Immunisation of jirds with B. malayi
TPI, or mice with the homologous protein from the rodent filaria Litomosoides sigmodontis, failed to induce neutralising
antibodies or protective immunity. In contrast, passive transfer of neutralising monoclonal antibody to mice prior to
implantation with adult B. malayi resulted in 60–70% reductions in microfilarial levels in vivo and both oocyte and
microfilarial production by individual adult females. The loss of fecundity was accompanied by reduced IFNc expression by
CD4+ T cells and a higher proportion of macrophages at the site of infection. Thus, enzymatically active TPI plays an
important role in the transmission cycle of B. malayi filarial parasites and is identified as a potential target for immunological
and pharmacological intervention against filarial infections.
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Introduction
Continued survival of parasitic helminths within their mamma-
lian host requires that they neutralise potentially protective
immune responses, generate energy and reproduce. Filarial
nematodes are particularly long-lived, tissue-dwelling parasites
which evade immunity and maintain transmission over many
years [1]. Over 100 million people are infected with lymphatic
filariae, such as Brugia malayi, and no vaccine is available for
human use [2,3]. Transmission occurs when blood-borne micro-
filarial larvae are taken up by a mosquito vector, generating
infective third-stage larvae which enter humans on a subsequent
blood-meal. Hence, any immunological means of blocking
microfilarial release would interrupt transmission.
As extracellular pathogens, the interaction of live parasites with
both the host and each other is likely to occur through a
combination of excretory/secretory (ES) products and surface
molecules [4,5]. Given the presumed involvement of ES molecules
in a range of processes essential for successful parasitism, they
represent attractive vaccine and drug targets. Because of this, we
and others have taken a proteomic approach to characterise the
complex mixture of proteins secreted by the human filarial
nematode Brugia malayi (B. malayi ES, BES) [6–9]. This revealed
that the most abundant ES protein of adult B. malayi is the
glycolytic enzyme triose phosphate isomerase (Bm-TPI, EC
5.3.1.1), predominantly from female worms. Detailed analysis of
the secretions of all life cycle stages has revealed that TPI is also
released by moulting L3 larvae early in infection [8].
TPI catalyses the interconversion of the triose phosphates
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate, an
essential step in glycolysis and gluconeogenesis [10]. Whilst TPI has
been detected in the ES products of other worms, such as the
cercariae and eggs of Schistosoma mansoni [11,12] and adult
Haemonchus contortus [13], the levels appear low compared to the
large amounts released by adult B. malayi [6–8]. Furthermore, there
is little or no secretion of other glycolytic enzymes, implying that
TPI is selectively secreted through an active process, rather than
simply leaching from compromised worms. This was supported by
the demonstration that TPI is approximately 20-fold enriched in
BES compared to a soluble extract of adult B. malayi [6].
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However, it is unclear why Brugia and other nematodes secrete
TPI given that glycolysis occurs in the cytosol. In this regard,
several reports indicate that TPI is a multifunctional protein. For
instance, TPI binds to the intracellular tail of the integrin aIIb in
platelets and may regulate integrin signalling [14]. TPI can also
function as an extracellular adherence molecule, and in this way
mediates the interaction of the fungal pathogen Paracoccidiodes
brasiliensis with both host epithelial cells and the extracellular
matrix proteins laminin and fibronectin [15]. Similarly, surface
associated TPI of Staphylococcus aureus contains a lectin activity that
can bind fungal sugars and promote bacterial adherence to, and
subsequent killing of, Cryptococcus neoformans [16,17]. Additionally,
studies of human TPI deficiency have shown that exogenous TPI
can complement TPI-deficient cells, suggesting that the secreted
enzyme may be taken up in a functional form by surrounding cells
[18,19].
Glycolytic enzymes, including TPI, have also been tested as
targets of protective immunity. Thus, a neutralizing monoclonal
antibody to S. mansoni TPI can confer up 40–50% reduction in
worm burden in mice [20] and DNA vaccination with S. japonicum
TPI reduces worm and egg burdens in experimentally infected
pigs and water buffalo [21,22]. Successful vaccination with
schistosome TPI is consistent with its induction of IFNc, a
cytokine associated with protective immunity against the larval
schistosomula [23]. Even in the Th2-dominated environment that
develops following schistosome egg production in mice, TPI
preferentially stimulates Th1 cytokines [24]. S. mansoni TPI can
also induce Th1 differentiation by T cells from unexposed humans
[25]. In other helminth species, certain glycolytic enzymes have
been similarly tested as vaccine candidates: for example, Onchocerca
volvulus fructose 1,6-biphosphate aldolase is strongly recognised by
antibodies from exposed but uninfected subjects, and can elicit a
50% reduction in larval survival in vaccinated mice [26].
However, studies on B. malayi have to date focussed solely on
the biochemical properties of glycolytic enzymes with a view to
development of new pharmacological inhibitors [27,28].
Since glycolysis plays a key role in filarial worm energy
metabolism [29–31], coupled with the unusually high level of
secretion of TPI, we investigated the role of Bm-TPI in B. malayi
infection. We confirmed that Bm-TPI is highly preferentially
secreted, enzymatically active, and an antibody target in both
infected mice and humans. Whilst vaccination with filarial TPI
failed to confer protection against challenge infection with B.
malayi or Litomosoides sigmodontis, antibody-mediated neutralisation
of Bm-TPI shows it is required for the optimal survival of
microfilariae within the mammalian host. As such, this parasite
enzyme represents a novel and rational target for intervention by
immunological or pharmacological means.
Results
Cloning and characterisation of recombinant Bm-TPI and
Ls-TPI
To study the role of filarial triose phosphate isomerases, we first
cloned the cDNA encoding this enzyme for expression as
recombinant proteins. Full-length Bm-TPI cDNA was amplified
by PCR from mixed adult B. malayi cDNA, cloned and confirmed
as identical to the annotated B. malayi gene (Bm1_29130 [32]). The
encoded 247-aa protein lacks a signal sequence, and has a
predicted molecular weight of 27,097 Da. Sequence analysis
shows a high degree of amino acid conservation with human (61%
identity), S. mansoni (58%) and C. elegans (76%) proteins, including
the AYEPVWAIGTG active loop and catalytic E165 (correspond-
ing to E166 in human TPI; [33]), as well as the other active site
residues, N10 (human N12), K12 (K14) and H94 (H96) (Fig. 1 A).
Recombinant Bm-TPI was expressed in bacteria and purified by
nickel resin affinity chromatography, appearing as a single band of
approx. 28 kDa by SDS-PAGE and a dominant molecular species
by mass spectrometry of 28,030 (data not shown). Functional
activity of recombinant Bm-TPI was confirmed by enzymatic
assay, in which it displayed typical Michaelis-Menten kinetics
indistinguishable from rabbit TPI with a Vmax of 715 U/mg and
a Km of 1.8 mM (Fig. 1 B). The activity of Bm-TPI was
compared to the homologous enzyme from the mouse filarial
parasite Litomosoides sigmodontis [34]. Ls-TPI has 94% (233/247)
amino acid identity to Bm-TPI (Fig. 1A), and following cloning of
the corresponding cDNA and bacterial expression, recombinant
protein showed similar enzyme kinetics to both Bm-TPI and rabbit
TPI (Fig. 1 B).
Abundant expression of Bm-TPI
Previous proteomic studies have indicated Bm-TPI is amongst
the most abundant proteins secreted by adult female B. malayi [6–
8]. Preferential secretion was confirmed by Western blot using a
polyclonal antiserum raised against rBm-TPI, which showed
significant enrichment of Bm-TPI in BES compared to somatic
extracts of adult worms, L3 larvae and microfilariae (Fig. 2 A).
Native secreted Bm-TPI was shown to be enzymatically active by
comparing BES with varying amounts of recombinant Bm-TPI.
This revealed that each mg of BES had equivalent enzymatic
activity to 370686 ng recombinant protein (Fig. 2 B). Enzymatic
activity in BES was abolished by heat denaturation (Fig. 2 B).
Immunohistochemistry of sections of adult male and female
B. malayi showed ubiquitous somatic expression pattern expected
of a glycolytic enzyme, but provided no clues as to the source of
secreted Bm-TPI by adult females (Fig. 2 C). Additionally,
surface staining of intact whole worms was not seen, indicating
that Bm-TPI is not shed from the cuticle of the parasite (data not
shown).
Author Summary
Triose phosphate isomerase (TPI) is a ubiquitous and
highly conserved enzyme in intracellular glucose metab-
olism. Surprisingly, the human lymphatic filariai nematode
parasite Brugia malayi, releases TPI into the extracellular
environment, suggesting a role in helminth survival in the
mammalian host. We first established that B. malayi-
infected humans and rodents generate TPI-specific serum
antibody responses, confirming presentation of this
protein to the host immune system. However, immunisa-
tion of rodents with B. malayi TPI did not induce
protection against infection. Furthermore, TPI from a
related parasite, Litomosoides sigmodontis, did not induce
protective immunity in mice. Notably, antibodies from
infected hosts did not neutralise the enzymatic activity of
TPI. We then generated twenty-three anti-TPI monoclonal
antibodies, of which only two inhibited enzymatic activity.
Transfer of neutralising antibody to mice prior to B. malayi
infection effected a 69.5% reduction in microfilarial levels
in vivo and a 60% reduction in microfilariae produced by
individual adult female parasites. Corresponding shifts in
the host immune response included reduced Th1 cytokine
production and enhanced macrophage numbers. Enzy-
matically active TPI therefore promotes production of the
transmission stage of B. malayi filarial parasites and
represents a rational target for new vaccine and drug
development to protect against filarial infections.
Brugia TPI Sustains Infection
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Antibody recognition of Bm-TPI by infected subjects
An important question is whether the prominent expression
of Bm-TPI results in a strong antibody response in infected
patients. We analysed serum samples from a cohort of B. malayi-
exposed residents of Rengat, Sumatra, Indonesia that were
classified into presumed uninfected subjects (‘‘endemic nor-
mals’’), asymptomatic microfilarial carriers, and patients with
chronic filarial pathology who are generally amicrofilaraemic
[35,36]. Individuals within each exposed group were found with
positive IgG responses against Bm-TPI compared to sera from
unexposed UK residents (Fig. 3 A). However, a greater
proportion of infected individuals suffering from lymphatic
pathology were seropositive (76%) compared to asymptomatic
microfilaremics (48%) and endemic normals (42%), and the
majority of strong responders were within the filarial pathology
group. In contrast, no antibody reactivity was detected against
mammalian TPI (using rabbit TPI which has 245/249 amino
acid identity with the human protein) (Fig. 3 B). An isotype
analysis of anti-Bm-TPI antibodies showed that reactivity was
confined to the IgG1 and IgG4 isotypes (Fig. 3 C–F); notably
IgG4 levels were higher to Bm-TPI in the pathology group,
although the Mf+ individuals display far higher IgG4 levels to
total B. malayi somatic antigens [35]. As we had previously
detected little anti-Bm-TPI antibody reactivity using 2-D
Western blots [6], the high level of reactivity found by ELISA
indicated that the epitopes are predominantly conformational
and denatured by SDS-PAGE electrophoresis, a conclusion
supported by the lack of immunoreactivity in the vast majority
of individuals to heat-treated Bm-TPI (Fig. S1 A–D).
Vaccination of rodents with filarial TPI does not confer
protection against challenge infection
We next assessed whether vaccination of Mongolian jirds
(Meriones unguiculatus), which are fully permissive to B. malayi
infection [37], with Bm-TPI would generate protective immunity
against challenge infection. In an initial experiment, animals were
vaccinated three times with either Bm-TPI or control protein
(BSA) in alum. Animals were infected intraperitoneally, with
serum antibody titres and worm burdens being determined at 8
weeks post-challenge. All infected animals made strong IgG1
responses against a somatic extract of B. malayi adults (data not
shown), but prior immunization with Bm-TPI induced .10 times
higher IgG1 titres against this protein (Fig. 4 A). Despite this
potent antibody response, and as shown in Fig. 4 B, there was no
significant reduction in worm burdens at 8 weeks of infection in
the Bm-TPI-immunized jirds (4466.5, vs BSA, 5567.0, p = 0.290).
In a further experiment, we reasoned that a longer duration of
infection might be required to see any protective effects induced by
vaccination with a largely adult-specific secretory product. As
such, jirds were immunised with Bm-TPI or BSA as before,
challenged and assessed 21 weeks later. Vaccination again induced
high titers of anti-TPI IgG1 (Fig. 4 C), but failed to provide any
Figure 1. Bm-TPI is conserved in sequence and enzymatic function. A. Amino acid alignment of Bm-TPI (XP_001897269) with Ls-TPI
(Hx2000032586), Ce-TPI (NP_496563), Sm-TPI (P48501), mouse TPI (NP_033441) and human TPI (NP_000356). B. Michaelis-Menten kinetics comparing
activity of recombinant Bm- and Ls-TPI with native rabbit TPI. Results are representative of multiple batches of enzymes.
doi:10.1371/journal.ppat.1003930.g001
Brugia TPI Sustains Infection
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protection, and indeed both adult worm (Fig. 4 D) and peritoneal
microfilariae numbers (Fig. 4 E) were slightly elevated compared
to the BSA control.
The jird model is one that tests immunity of a rodent host to a
human parasite, with parasites resident in the peritoneal cavity
rather than their physiological niche of lymphatic vessels (for adult
worms) and blood (for microfilariae). We therefore conducted a
parallel test of protective capacity of TPI in a natural murine
model of filarial infection, L. sigmodontis, which resides in the
pleural cavity [34]. Mice were vaccinated three times with Ls-TPI
in alum, and then challenged with L. sigmodontis L3. The results
were similar to those observed with B. malayi in the jird: while
specific anti-TPI antibodies were strongly boosted (Fig. 4 F), adult
worm numbers were unchanged at day 70 post-challenge (Fig. 4
G) and when worm lengths were measured no differences were
seen (data not shown). Moreover, circulating microfilarial numbers
were not significantly diminished in immunized animals (Fig. 4
H).
Blockade of Bm-TPI does not impair parasite survival in
vitro
One explanation for the poor level of protection induced by
vaccination with Bm-TPI is the failure to generate high titres of
neutralizing antibodies. Indeed, the sera from vaccinated jirds with
high anti-Bm-TPI titres (Fig. 4 B) had limited ability to block Bm-
TPI catalytic activity, leaving 75% of isomerase activity intact
(Fig. 5 A). Similarly, polyclonal mouse serum raised to Bm-TPI
effected only a slight reduction in enzyme activity (Fig. 5 B), whilst
human sera from individuals strongly reactive to Bm-TPI (Fig. 3)
failed to inhibit the enzyme at all (Fig. 5 C). This suggested that
both immunisation and natural infection generated only limited
amounts of anti-Bm-TPI antibodies directed at the active site. To
confirm this, a panel of mouse monoclonal antibodies specific for
Bm-TPI were generated. Only 2 of 23 (9%) anti-Bm-TPI clones
were capable of blocking enzyme activity (Fig. 5 D), of which one
anti-Bm-TPI mAb (clone 1.11.1, IgG1 isotype) was used in
subsequent experiments.
Figure 2. Adult worms preferentially secrete enzymatically active Bm-TPI. A. Western blot for Bm-TPI of 1 mg parasite extract (somatic
extacts of L3 (L3A), Mf (MfA) and adult (BmA) or three independent batches of adult BES. Recombinant Bm-TPI included as a positive control. B. TPI
activity in multiple independent batches of native BES or heat-denatured (hd)–BES. ** p,0.01 by t-test. C. Immunofluorescence of adult B. malayi
female with polyclonal mouse anti-Bm-TPI (left panels) and control normal mouse serum (right panels) applied to longitudinal (Upper panels) and
transverse (lower panels) sections. Scale bar represents 100 mm.
doi:10.1371/journal.ppat.1003930.g002
Brugia TPI Sustains Infection
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MAb 1.11.1 was able to effectively block recombinant Bm-TPI
enzymatic activity in a dose-dependent manner (Fig. 5 E), with a
calculated Ki of ,1 mg/ml for 100 ng Bm-TPI. In contrast, no
blockade of either mammalian (Fig. 5 E), or perhaps surprisingly, L.
sigmodontis TPI (Fig. 5 F) was seen. Most importantly, anti-Bm-TPI
blocked native Bm-TPI as assessed by its ability to inhibit TPI
activity present in BES (Fig. 5 G).
We then tested whether antibody inhibition of TPI enzymatic acti-
vity could cause parasite death in vitro. However, adult male and female
B. malayi were able to survive in culture for sustained periods ($3 days)
Figure 3. Anti-Bm-TPI antibody levels in B. malayi-infected human filariasis patients. A. Human anti-Bm-TPI IgG levels measured by ELISA
(OD values). Each data point represents an individual normal human serum (NHS) or serum from filariasis-exposed subjects classified as endemic
normal (EN), microfilaraemic (MF) or chronic pathology (Path). B. IgG ELISA responses of the same patient groups to mammalian (rabbit) TPI. C–F.
IgG1-IgG4 isotype-specific anti-Bm-TPI levels in the same patient groups. ** p,0.01, significance compared to NHS by ANOVA. Lines in (A–F)
represent median values.
doi:10.1371/journal.ppat.1003930.g003
Brugia TPI Sustains Infection
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in the presence of up to 500 mg/ml mAb clone 1.11.1 (data not shown).
This suggested that whilst the antibody can inhibit secreted TPI, it
cannot act directly on the parasite, and that in vitro worm survival over
this period does not depend on TPI activity in the culture medium.
In vivo neutralization of Bm-TPI reduces microfilaraemia
Next, we tested whether MAb 1.11.1, with specific neutralizing
ability, would alter the course of filarial infection in vivo. Mice were
implanted intraperitoneally with 10 B. malayi adults (8 female, 2
male) and treated every 1–2 days with 200 mg anti-Bm-TPI mAb
or IgG1 isotype control. Transfer of mAb 1.11.1 mAb established
serum anti-Bm-TPI titres 35-fold greater than develop normally in
response to infection, as seen in mice given the isotype control
antibody (Fig. 6 A). Furthermore, transfer of 1.11.1 mAb
conferred on recipient serum the ability to effectively block TPI
enzymatic activity in vitro (Fig. 6 B). Despite this, live adult
Figure 4. Vaccination with Bm-TPI does not curtail infection. A. Immunisation induces high titers of week 8 post-challenge anti-Bm-TPI IgG1
antibodies in vaccinated jirds, compared to animals immunised with BSA control. B. Week 8 post-challenge adult B. malayi worm burdens in Bm-TPI
and BSA vaccinated jirds. C. Anti-Bm-TPI IgG1 titers remain high by week 21 post-challenge in vaccinated jirds, compared to BSA control animals. D.
Week 21 post-challenge adult B. malayi worm burdens in Bm-TPI and BSA vaccinated jirds. E. Peritoneal B. malayi microfilarial counts in jirds at week
21 post-infection previously vaccinated with BSA or Bm-TPI. F. Immunisation induces high titers of day 70 post-challenge anti-Ls-TPI IgG1 antibodies
in vaccinated BALB/c mice, compared to animals immunised with BSA control. G. Day 70 post-challenge adult L. sigmodontis worm burdens in Ls-TPI
and BSA vaccinated BALB/c mice. H. Day 70 post-challenge blood L. sigmodontis microfilarial counts in Ls-TPI and BSA vaccinated BALB/c mice.
Dotted lines in A, C and F represent background antibody titers naı¨ve jird or mouse sera. n.s. non-significant, ** p.0.01, *** p.0.001, **** p.0.0001,
by t-test.
doi:10.1371/journal.ppat.1003930.g004
Brugia TPI Sustains Infection
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worms were recovered from the peritoneal cavities of both groups
of infected mice after 28 days (Fig. 6 C) with no significant
differences in male or female numbers (data not shown). In
contrast, numbers of peritoneal microfilariae (Mf) were signifi-
cantly reduced in anti-Bm-TPI-treated mice, being 69.5% lower
than in animals given isotype control (Fig. 6 D) indicating that
Bm-TPI activity is required for either the release or survival of live
Mf.
Using Mf obtained from non-immunised jirds, we next
demonstrated that in vitro Bm-TPI blockade was unable to kill
Mf (Fig. 6 E), indicating that the antibody is not directly toxic to
Mf, and that neutralisation of TPI is not detrimental to this stage
of the parasite. Likewise, in vitro Bm-TPI blockade did not reduce
Mf production by adult females obtained from non-immunised
jirds (Fig. 6 F). Instead, when we cultured adult females from the
peritoneal cavity of mice following in vivo anti-Bm-TPI or isotype
treatment, parasites from anti-Bm-TPI treated mice produced
,60% fewer MF in vitro, consistent with Bm-TPI blockade
compromising parasite fitness in terms of female reproductive
output in vivo (Fig. 6 G). In particular, a much greater proportion
Figure 5. Generation of neutralizing antibodies to Bm-TPI. A. TPI enzyme activity in presence of 10% serum from jirds infected for 21 weeks
with B. malayi following immunisation with BSA or Bm-TPI. * p,0.05 by t-test. B. TPI enzyme activity in presence of 10% polyclonal anti-Bm-TPI serum
from BALB/c mice or naive mouse serum (nms). C. TPI enzyme activity in presence of 10% serum from human filariasis patients. Serum was used from
the 5 strongest anti-Bm-TPI reactors (black circles) or 5 non-reactors (white circles) from each group (Fig. 3). D. Generation of antibody specificities
that neutralise Bm-TPI activity is a relatively rare event. Ability of a panel of murine mAb specific for Bm-TPI (data not shown) to inhibit enzyme
activity was determined. Clones with neutralising capacity are shown in red. E. Specificity of neutralizing mAb 1.11.1 for Bm-TPI (black bars) and not
rabbit TPI (white bars). F. Specificity of neutralizing mAb 1.11.1 for Bm-TPI (black bars) and not Ls-TPI (grey bars). A, B, E and F are representative of
multiple batches of recombinant enzyme. G. Neutralisation of native Bm-TPI activity in BES (4 independent batches) by mAb 1.11.1. MOPC31C IgG1
myeloma protein was used as a control. Dotted lines in (A–D) represent enzyme activity in the absence of serum or antibody (normalised to 100%).***
p,0.001 by t-test.
doi:10.1371/journal.ppat.1003930.g005
Brugia TPI Sustains Infection
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of adult female worms from anti-TPI-treated jirds completely
failed to release live Mf during in vitro culture (45.2% compared to
12.5% in isotype-treated controls).
Analysis of uterine contents from individual female B. malayi
revealed that TPI blockade led to a significant decrease in the number
of unfertilised oocytes (Fig. 6 H). Whilst oocytes were the
predominant developmental stage in females obtained from isotype
treated mice (Fig. S2 A), anti-Bm-TPI treatment led to the
accumulation of smaller developmental stages that appeared damaged
or partially degraded (Fig. S2 B). In contrast, no significant difference
Figure 6. In vivo Bm-TPI blockade reduced microfilarial production by adult females. A. Serum titers of anti-Bm-TPI antibodies following
multiple injections (166) with 1.11.1 anti-Bm-TPI mAb or control IgG1 myeloma protein MOPC31C in mice 28 days following transplant of adult B.
malayi worms. Representative of two experiments. **** p,0.0001 by ANOVA. B. Ability of serum from recipient mice to neutralize Bm-TPI activity.
Sera were compared from naı¨ve mice or day 28 post-Bm adult implant mice treated with MOPC or 1.11.1 anti-Bm-TPI mAb as (A). Dotted line
indicates enzyme activity in absence of serum. C. Day 28 peritoneal worm burdens in recipients of MOPC31C or 1.11.1 anti-Bm-TPI Mab as (A). D. Day
28 peritoneal microfilarial counts in recipients of MOPC31C or 1.11.1 anti-Bm-TPI Mab as (A). Data in C and D are combined results from 3
independent experiments, with 5–6 mice per group. ** p,0.01 by t-test. E. Live MF numbers following 3 day in vitro culture alone, with MOPC31C or
with 1.11.1. Initial MF input was 15,000 and data is from 3–4 wells per treatment, and is representative of two experiments. F. Live MF numbers
recovered from individual female worms obtained from the peritoneal cavity of untreated jirds. Worms were cultured for 2 days alone, with MOPC31C
or with 1.11.1, and is representative of two experiments. G. Live Mf numbers by individual female worms (2 day cultured) obtained from the
peritoneal cavity of mice injected multiple times with MOPC31C or with 1.11.1. for 14 days. * p,0.05 by Mann-Whitney. Data are pooled from two
independent experiments. H. Embryogram of uterine contents of individual adult female B. malayi parasites recovered from peritoneal cavity of mice
(n = 4) injected multiple times for 14 days with MOPC31C or 1.11.1 anti-TPI antibody. I. Microfilarial numbers in blood 24 hours following i.v. transfer
into mice receiving control MOPC31C and 1.11.1 anti-TPI antibodies.
doi:10.1371/journal.ppat.1003930.g006
Brugia TPI Sustains Infection
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was observed in the number of Mf transferred directly into antibody-
treated mice (Fig. 6 I) again implying that TPI blockade targets
female egg production, thereby reducing subsequent release of live Mf.
Macrophage expansion in TPI-neutralised mice. To
establish if the stronger immunity in the TPI-neutralised setting
is associated with changes in immune cell types, we studied the
frequency and phenotype of key cell populations in B. malayi-
implanted mice. Administration of 1.11.1 did not affect overall cell
recruitment to the peritoneal cavity infection site (Fig. 7 A), but
TPI blockade resulted in a greater proportion of CD11b+F4/80+
macrophages within this compartment (Fig. 7 B). Analysis of
markers of alternative activation of macrophages showed that
Chi3L3 (Ym1) and RELMa expression was uniformly high in
CD11b+ cells from all infected mice, irrespective of treatment
(Fig. 7 C), indicating alterations in quantitative expansion rather
than the qualitative nature of the macrophage population. In
contrast to increased frequencies of macrophages, we also found
reduced eosinophilia in the anti-TPI-treated mice (Fig. 7 D).
Within the CD4+ T cell subset, Th2 responses measured by
total IL-4-expressing CD4+ T cells, also showed little difference in
antibody recipients (Fig. 7 E), but there was a significant
reduction in IFN-c expression, indicating diminished Th1
responsiveness in the absence of TPI enzymatic activity (Fig. 7
F). To test whether Bm-TPI directly stimulates the expansion of
Th1 cells, transgenic DO11.10 ovalbumin-specific T cells were co-
cultured with ovalbumin peptide and TPI, or co-transferred to
naı¨ve mice together with ovalbumin antigen and TPI i.p.
However, cytokine responses in TPI recipients were unaltered
both in vitro and in vivo (Fig. S3) arguing that the effects of TPI
on the effector T cell compartment occur in the setting of an active
parasite infection. Finally, we examined the activation of Foxp3-
expressing regulatory T cells in mice receiving B. malayi implants
which has been previously reported, including the induction of
CD103 expression [38]. Frequencies of Foxp3+ Tregs expressing
the marker CD103 were elevated in all infected mice irrespective
of 1.11.1 administration (Fig. 7 G).
Discussion
Parasite mediated-immunomodulation relies on products se-
creted into the environment of the pathogen in vivo, and the
analysis of in vitro released ‘‘excretory-secretory’’ (ES) proteins has
provided an approximation of the spectrum of released macro-
molecular components. We and others have identified Bm-TPI as
a dominant product secreted by adult B. malayi worms [6–9], and
here confirm not only the preferential secretion of this enzyme by
live adult worms in vitro, but show, by its antigenicity in infected
mice and humans, that it is exposed to the immune system in vivo.
How TPI is secreted, in the absence of a signal peptide, remains
unclear and its ubiquitous expression throughout the somatic
tissues of B. malayi does not provide any pointers to a particular
route of secretion. Possibly, as secretion is far higher in female
worms than males [7], TPI could be released along with
microfilariae from the female genital tract.
Filarial TPIs, from both B. malayi and L. sigmodontis, are active
enzymes with catalytic properties very similar to those of
mammalian homologues. Immunologically, however, TPIs from
mammals and nematodes are non-cross-reactive, and indeed we
generated monoclonal antibodies capable of distinguishing
between the two filarial enzymes. Hence, in human infections
anti-Bm-TPI antibodies were not found to be auto-reactive with self
TPI, suggesting that the pathologies of lymphatic inflammation,
edema and fever are not linked to an autoimmune reaction against
human TPII. In this respect, filarial infection differs from that of
Trypanosoma cruzi, which induces auto-antibody production against
host TPI [39].
When comparing the levels of anti-Bm-TPI between infected
individuals we noted that titres are greater in cases of filarial
pathology in whom circulating microfilariae are generally absent.
Because of this, we tested the potential of Bm-TPI to provoke
protective immunity against B. malayi in animal models. In the
jird, M. unguiculatus, which is fully susceptible to infection with
the mosquito-borne L3 stage, both total worm and Mf numbers
were unchanged in vaccinated animals following peritoneal
infection. However, vaccination did not generate high levels of
neutralizing antibody in terms of the catalytic activity of the
enzyme, which may be more efficient than removal of TPI by
complexing and opsonization. By screening a large panel of
murine monoclonals, we selected a neutralizing antibody that
conferred, in a mouse peritoneal implantation model, immunity
against the Mf stage.
We also noted that TPI blockade inhibits the development of
eggs within the adult female worm, reflecting a loss of fitness in the
parasite that may have either or both a metabolic or immuno-
logical cause. Several other regimes have been shown to limit the
release of viable microfilariae by filarial parasites. In this regard,
antibiotic-mediated depletion of endosymbiotic Wolbachia causes
degeneration of B. malayi oocytes, embryos and microfilariae
[40,41], although in this setting parasite metabolism is likely to be
more heavily compromised. An immunological cause of reduced
parasite fecundity can also be illustrated in mice immunised with
L. sigmodontis Mf, .70% of which fail to develop microfilaraemia,
due to an inhibition of embryogenesis to the pretzel stage [42].
The selective effect on microfilarial levels recapitulates a
consistent, but unexplained, feature of filarial nematode infections.
In both humans and animal models, cryptic amicrofilaraemic
infections can occur in which immunity appears to operate only
against the microfilarial stage. For example, cats infected with
B. pahangi often became Mf-negative and yet remained seropositive
for circulating filarial antigen and were found to harbour live adult
worms at autopsy [43]. Similarly, circulating antigen tests in
humans identify a significant proportion of Mf-negative infected
subjects. However, in the majority of cases, it appears that natural
infection does not generate blocking antibody to TPI suggesting
the possibility that the active site has in some manner evolved to
minimise stimulation of neutralising antibody. The surprising
finding that such antibodies do not cross-react between the highly
conserved TPIs from two related filarial species reflects a further
unusual property of these proteins.
To establish whether TPI enzyme activity is essential for its
extracellular function, and whether only blocking antibodies can
be protective, it would be desirable to test multiple panels of
monoclonals and to conduct experiments with pharmacological
inhibitors of filarial TPI. Future studies may also develop blocking
antibodies against L. sigmodontis TPI which would permit the
analysis of the biological role of TPI during the full course of
infection in mice, as the murine antibodies we describe here
cannot be administered to other rodent species for extended
periods of time.
In addition, species-specific chemical TPI inhibitors have been
described which target non-conserved amino acids, particularly at
the dimer interface e.g. Trypanosoma cruzi [44], Trypanosoma brucei
[45], Plasmodium falciparum [46] and Giardia lamblia [47]. Small
molecule inhibitors may be superior to antibody-mediated
blocking as they offer the advantage of penetration into the
parasite itself, rather than just inhibition of secreted form, and are
likely to be more effective against the adult worms which, as we
show, survive even in the face of very high neutralising Ab titres.
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The in vivo consequences of TPI neutralisation may link poor
microfilarial survival with shifts in the anti-parasite immune
response. Thus, the reduction in IFN-c production by peritoneal
cavity CD4+ T cells may be an indirect effect of diminished
numbers of microfilariae, as this stage (unusually) induces Th1
responsiveness [48–50]. Similarly, the reduced eosinophilia could
Figure 7. Altered T cell, eosinophil and macrophage responses in mice receiving neutralising anti-Bm-TPI monoclonal antibody. A.
Peritoneal cell recruitment in recipients of 1.11.1 anti-Bm-TPI monoclonal antibody or control IgG1 myeloma protein MOPC31C, in mice 28 days
following transplant of adult B. malayi worms. B. Peritoneal CD11b+ F4/80+ macrophages as in (A). C. Intracellular expression of Ym-1 and RELMa by
peritoneal macrophages (CD11b+ F4/80+ Ly6G2 siglecF2) in mice 14 days following transplant of adult B. malayi parasites with 1.11.1 anti-Bm-TPI
monoclonal antibody or control IgG1 myeloma protein MOPC31C. Representative of 4 mice per group. D. Peritoneal CD11b+ siglecF+ cells as in (A). E.
Intracellular IL-4 production by CD4+ peritoneal T cells as in (A) F. Intracellular IFN-c production by CD4+ peritoneal T cells as in (A). G. Frequency of
CD103+ expression among Foxp3+ Tregs as in (A). Data in (A–B, D–G) are pooled from 4 independent experiments.
doi:10.1371/journal.ppat.1003930.g007
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reflect weaker stimulation from the microfilarial stage. Interest-
ingly, this argument would suggest that microfilariae normally
dampen macrophage expansion in vivo, a point which has yet to
be experimentally investigated.
The finding that TPI is also secreted by plant-parasitic
nematodes [51], and the importance of glycolysis in adult
B. malayi [31], are consistent with TPI release facilitating adult
worm metabolism and being required for optimal fecundity and
Mf production in vivo. It is also possible that the heightened
frequency of alternatively-activated macrophages imposes immu-
nological damage on adult worms, thereby reducing their ability to
reproduce, and such damage may of course be more easily
achieved if the target is also metabolically compromised. In any
event, our data present a remarkable immunological strategy for
transmission in the filarial nematode: adult females release TPI
which promotes oogenesis, and so increases the number of their
offspring. Hence, in the mouse model at least, TPI neutralisation
inhibits this process and reduces the microfilarial burden.
Materials and Methods
Animals, human samples, parasites and production of
BES
BALB/c mice and Meriones unguiculatus jirds were bred in-house.
B. malayi (obtained originally from TRS Laboratories, Athens,
Georgia, USA) was maintained in Aedes aegypti mosquitos and jirds.
Infective larvae (L3) were recovered from mosquitos 12–14 days
following feeding on microfiariae- (Mf-) containing blood, as
detailed previously [52]. Jirds were infected with up to 600 L3;
adult worms and microfilariae were recovered from the peritone-
um approximately 4 months later. The Litomosoides sigmodontis life
cycle was maintained, and L3 larvae or adult worms recovered, as
described previously [53]. Somatic extracts of worms (from adults,
BmA; from L3, L3A and from Mf, MfA) and BES were produced
as previously described [6].
Ethics statement
All animal protocols adhered to the guidelines of the UK Home
Office, complied with the Animals (Scientific Procedures) Act
1986, were approved by the University of Edinburgh Ethical
Review Committee, and were performed under the authority of
the UK Home Office Project Licence number 60/4105. Human
serum samples were taken from archived stocks derived from a
study in Rengat, Indonesia that has been previously described [54]
and in which informed consent was obtained from all patients
before clinical and parasitologic investigation and blood with-
drawal in accordance with the guidelines of the Indonesian
Department of Health and Human Services.
Cloning and recombinant expression of Bm-TPI and Ls-
TPI
Total RNA was extracted from adult mixed sex B. malayi and
L. sigmodontis using TRIzol (Invitrogen), and reverse transcribed
with MMLV reverse transcriptase (Stratagene) using standard
protocols. A partial sequence (nt 1–664) for Ls-TPI (LS00587) was
obtained from NEMBASE v4 (http://www.nematodes.org/
nembase4/index.shtml). The missing 39 end was obtained by 39
RACE using Invitrogen Gene Racer Core kit with RACE-ready
cDNA and the forward primer ATG TCT CGA AAG TTT CTA
GTT as previously described [55]. The resultant full-length
nucleotide sequence has been submitted to the European
Nucleotide Archive with the Accession Number HG329626. The
following PCR primers were used for amplification; Bm-TPI
forward primer CAT ATG TCG CGA AAA TTT CTT, Ls-TPI
forward primer CAT ATG TCT CGA AAG TTT CTA GTT,
Bm-TPI and Ls-TPI reverse primer CTC GAG ATC ACG TGC
ATG AAT AAT TT (restriction sites are underlined). PCR
conditions were as follows: 35 cycles of 95uC 30 sec, 60uC 30 sec,
and 72uC 2 min. Reaction products were separated on 1%
agarose gels, visualised using ethidium bromide, and the 750-bp
amplicons excised and purified (QIAquick gel extraction, Qiagen).
PCR products were cloned into pGEM-T vector (Promega) and
transformed into E. coli JM109 (Promega) for overnight colony
formation. Minipreps from positive colonies were sequenced. An
internal Nde1 site was removed in both Bm-TPI and Ls-TPI by
PCR-based site-directed mutagenesis (CATATG replaced with
CATACG, a synonymous mutation, in-frame codon underlined),
using 50 ng of parental plasmid, Deep Vent DNA polymerase
(New England Biolabs) and the following PCR primers : Bm-TPI
forward primer CCT TAT TTA TCA TAC GTT AAG GAG
AAA, Bm-TPI reverse primer TTT CTC CTT AAC GTA TGA
TAA ATA AGG, Ls-TPI forward primer CCA TAT TTG TCA
TAC GTC AAG GAA AAA GTT, Ls-TPI reverse primer AAC
TTT TTC CTT GAC GTA TGA CAA ATA TGG. PCR
conditions were as follows: 18 cycles of 95uC 30 sec, 55uC 1 min,
and 75uC 8 min. Reaction products were digested with Dpn1 (New
England Biolabs) for 2 hours at 37uC to remove parental plasmid,
purified as for plasmid preps, and then used to transform E. coli
JM109, and grown as before. Coding sequences for Bm-TPI and
Ls-TPI were ligated into linearised pET29c (Novagen) following
digestion with Nde1 and Xho1. Protein expression was induced in
BL21(DE3) cells with 1 mM IPTG for 3 hours at 37uC. Bacteria
were pelleted and lysed in Bug Buster supplemented with 25 U/ml
benzonase (Novagen) for 20 min at room temperature. C-terminal
His-tagged proteins were purified by metal affinity chromatogra-
phy using Hi-Trap chelating Hp columns on an AKTAprime (GE
Healthcare). Eluted fractions containing recombinant TPI protein
were pooled and dialysed into PBS. Endotoxin was removed using
Detoxi-Gel Endotoxin Removing Columns (Thermo Scientific).
Recombinant TPI was stored at 2 mg/ml at 280uC.
Enzymatic assays
Enzymatic activity of TPI was determined in the reverse
direction (conversion of DHAP to G3P) as described by Lambeir et
al [56]. Standard reaction conditions were 100 mM TEA-HCl
pH 7.6, 1 mM EDTA, 0.16–10 mM DHAP (1.5 mM if not
indicated), 1 mM NAD+, 5 mM disodium hydrogen arsenate and
10 mg rabbit GAPDH. Reactions were initiated with 100 ng TPI
in a total volume of 150 ml. Rabbit TPI and all above reagents
were from Sigma. The initial reaction rate was calculated by the
change in NADH absorbance at 340 nm with a Nanodrop 2000
(Thermo Scientific). Enzyme activity was calculated in units
(1 U = 1 mmol substrate formation min21 mg21 enzyme at 25uC).
Calculations were confirmed using a NADH standard curve
(Sigma). To determine the level of TPI activity in BES, reactions
were initiated with 500 ng of BES or heat denatured BES (95uC
30 min), and compared to 25–400 ng of Bm-TPI. To assess the
inhibitory potential of serum from immunised animals, enzymatic
assays were performed in the presence of 10% test or control
serum. Enzyme blockade by monoclonal antibodies was assessed
in the range 0.5–50 mg/ml, and an isotype control mouse IgG1
MOPC31C was used where indicated. In these instances,
enzymatic activity was calculated as percentage activity compared
to the relevant control.
Human, jird and mouse antibody and cytokine ELISA
Recombinant Bm-TPI, rabbit TPI (Sigma), BSA or BmA were
coated (1 mg/ml in 0.06 M carbonate buffer pH 9.6) onto
Brugia TPI Sustains Infection
PLOS Pathogens | www.plospathogens.org 11 February 2014 | Volume 10 | Issue 2 | e1003930
Maxisorb 96 well Immunoplates (Nunc) overnight at 4uC. Plates
were blocked in 2% BSA (mouse and human sera) or 1% casein
(jird sera) in tris-buffered saline/0.05% tween 20 (TBST) for
2 hours at 37uC. Human IgG responses to Bm-TPI were tested
using sera (1/100 dilution) from a previously characterised
Indonesian B. malayi endemic study population [57]. Individuals
were classified into three clinical groups, elephantiasis (pathology)
patients, asymptomatic microfilaraemics, and endemic normals.
Normal human sera (NHS) were obtained from non-exposed UK
residents. IgG binding was detected using peroxidase labelled anti-
human IgG (1/1000, DakoCytomation), or anti-human IgG1,
IgG2, IgG3 or IgG4 (1/5000, The Binding Site). Plates were
developed using ABTS peroxidase substrate (KPL), and measured
with an Emax microplate reader (Molecular Devices). Samples
were considered positive if they exceeded the mean value plus 3
standard deviations of nonendemic human serum samples. Jird
sera (1/100 dilution) antibody levels were measured using
peroxidase labelled anti-mouse IgG1 (1/2000, Southern Biotech).
BALB/c anti-Bm-TPI titres were determined with doubling
dilutions of sera (1/50 onwards) and anti-mouse Ig peroxidase
(1/2000, DakoCytomation).
Polyclonal and monoclonal antibody production
For polyclonal antibody production, BALB/c mice were
immunised i.p. with 50 mg Bm-TPI in alum, and then boosted
with 10 mg Bm-TPI i.p. in alum on days 28 and 35. Serum was
recovered on day 42. For monoclonal antibody production,
BALB/c mice were immunised with 50 mg Bm-TPI, and then
boosted with 1 mg Bm-TPI in PBS i.v. on days 28, 29 and 30.
Spleens were recovered on day 32 and fused with SP2 as before
[58]. Cells were screened for Bm-TPI binding by ELISA, and
positive wells were tested for Bm-TPI blocking ability in the above
enzymatic assay. From this a blocking hybridoma was obtained,
and cloned through two rounds of limiting dilution, resulting in
anti-Bm-TPI clone 1.11.1. This was found to be an IgG1 using
mouse antibody isotype kit (Isostrip, Roche). Monoclonal antibody
was purified from culture supernatants using HiTrap protein G
HP columns and an AKTAprime, and dialysed into PBS. Control
mouse IgG1 MOPC31C was produced in the same way from cells
sourced from ECACC.
Western blots
BES and somatic extracts of L3, MF and mixed adult B. malayi
(1 mg) were run on SDS-PAGE gels and blotted onto nitrocellulose
membranes as previously described [6]. Following blocking in 5%
milk powder/TBST (2 hours room temperature), membranes
were probed overnight at 4uC with 1/500 mouse polyclonal anti-
Bm-TPI, washed extensively in TBST and the incubated with 1/
2000 rabbit anti-mouse Ig HRP (1 h, room temperature;
DakoCytomation). Following further washing in TBST, blots
were developed using ChemiGlow West (Alpha Innotech) and
imaged using a FluorChem SP (Alpha Innotech).
Immunohistochemistry
Adult B. malayi were mounted in Cryo-M-Bed (Bright Instru-
ments), frozen on dry ice, and 5 mm sections cut using a Leica
CM1510S cryotstat. Air dried sections were fixed in 100% acetone
(10 min), washed twice with PBS (20 min), and stained in a
humidified chamber with 1/100 dilution mouse anti-Bm-TPI sera
(generated as above) in 1% FCS/PBS (1 hour at room temper-
ature). Control sections were similarly treated with naı¨ve mouse
sera. Following extensive washing in PBS, sections were incubated
with 1/100 goat anti-mouse IgG TRITC (Sigma) as above,
washed in PBS, then mounted with Vectashield (Vector labs).
Sections were analysed with an Olympus BX50 fluorescent
microscope and Openlab software (PerkinElmer).
Vaccination regimes
Meriones unguiculatus jirds were immunized with 200 mg of Bm-
TPI or BSA i.p. in alum adjuvant and then boosted with sub-
cutaneous injections of 50 mg protein in alum at weeks 5 and 6.
Jirds were challenged with 190 B. malayi L3 i.p. at week 8 post-
immunisation. Infection was allowed to progress 8 weeks in the
first experiment and 16 weeks in the second experiment. For Ls-
TPI vaccination, BALB/c mice were immunised with 50 mg Ls-
TPI or BSA in alum, and then boosted on weeks 4 and 5 with
25 mg protein in alum. Mice were infected sub-cutaneously on
week 7 post-immunisation with 30 L. sigmodontis L3, and infections
were terminated at week 10 post-infection.
In vivo Bm-TPI neutralisation and embryograms
Surgical implant of adult B. malayi (8 females and 2 males) into
the peritoneal cavity of BALB/c mice was performed as previously
described [50]. Mice were given 200 mg of anti-Bm-TPI clone
1.11.1 mAb or MOPC31C isotype control every 1–2 days over the
course of a 14–28 day infection. Embryograms were performed on
recovered female parasites exactly as [42]. For in vivo microfilariae
transfer, Mf from the peritoneal cavity of infected jirds (16105)
were transferred i.v. in 200 ml RPMI1640 into BALB/c recipients,
which were then injected with 200 mg antibody as above.
Circulating Mf numbers were determined by tail bleed 24 hours
later.
FACS analysis, cell culture and transfer
Cells were recovered from infected mice by peritoneal wash
[38], washed into FACS buffer (PBS +0.5% BSA +0.05% sodium
azide) Fc receptors blocked with 0.5 mg/ml rat IgG on ice for
10 minutes, then stained variously with anti-CD11b Pacific Blue
(Biolegend; clone M1/70) anti-siglecF (PE or PE CF-594
conjugates, BD Pharmingen; clone E50-2440), anti-Ly6G APC-
Cy7 (Biolegend; clone 1A8) and anti-F4/80 (FITC or PerCP
conjugates, Biolegend; clone BM8). For macrophage alternate
activation analysis, cells were fixed and permeablised (eBioscience,
as per manufacturer’s instructions) before intracellular staining
with anti-RELMa (unlabeled rabbit polyclonal; PeproTech,
followed by rabbit Ig labeling reagent; Invitrogen) and anti-Ym-
1 (biotin-conjugated mouse chitinase 3-like 3; R&D, followed by
streptavidin PE-Cy7; Biolegend). For intracellular cytokine stain-
ing, peritoneal cells were re-stimulated ex vivo in complete
RPMI1640 media (supplemented with 10% FCS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin) with
1 mg/ml ionomycin, 500 ng/ml PMA and 10 mg/ml Brefeldin A
(all Sigma) for 4 hours at 37uC. Following FcR block, cells were
surface stained with anti-CD4 PerCP (clone RM4-5), fixed and
permeabilised (BD Pharmingen Cytofix/Cytoperm) and then
intracellular stained with anti-IFNg APC (clone XMG1.2) and
anti-IL-4 PE (clone 11B11). Relevant isotype control stains were
included. Alternatively, CD4+ cells were purified from the spleens
of naı¨ve BALB/c mice using MACS beads and columns (Miltenyi
Biotec), according to the manufacturer’s instruction, and stimu-
lated in complete RPMI1640 for 3 days in the presence of 1 mg/ml
anti-CD3 (clone 145-2C11) and 0.5 mg/ml anti-CD28 (clone
37.51) with varying amounts of recombinant Bm-TPI. Cells were
then washed, resuspended in fresh media and stimulated with
PMA and ionomycin in the presence of Brefeldin A as above. For
in vivo transfers of ovalbumin-specific DO11.10 cells, BALB/c mice
were injected i.p. with 2610e6 DO11.10 splenocytes (equivalent to
approx 46105 CD4+ cells, data not shown). The next day, mice
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were given 0.56106 dendritic cells i.p. pulsed overnight with LPS
(100 ng/ml, Sigma) and ovalbumin peptide (pOVA) residues 323–
339 (20 mg/ml, Invivogen), then subsequently injected on days 0,
1, 3 and 5 with 100 mg rBm-TPI or PBS control. Control mice
were given PBS rather than dendritic cells. At day 7, spleens and
peritoneal cells were harvested, stimulated as above and stained
with biotin anti-mouse TCR DO11.10 (clone KJ1-26) followed by
streptavidin-APC conjugate. Dendritic cells were generated in vitro
from mouse bone marrow in the presence of GM-CSF [59].
Antibodies were from Biolegend unless stated.
Statistical analysis
Statistical significance was determined using Prism 6 (Graphpad
Software Inc.). For comparison between two groups, unpaired
Student’s t-test or Mann-Whitney U-test was used dependent on
data normality. Multiple comparisons used one-way ANOVA
followed by Tukey’s test.
Supporting Information
Figure S1 Human antibodies to Bm-TPI recognise
conformational epitopes. IgG1 human ELISA reactivity to
‘‘native’’ or heat-denatured recombinant Bm-TPI. Sera is from (A)
non-exposed UK residents, (B) endemic normals, (C) microfilare-
mics, and (D) pathology patients. Only sera producing a positive
signal were included in B–D.
(PDF)
Figure S2 Bm-TPI neutralisation impairs embryogene-
sis. Representative pictures of uterine contents of adult female
B. malayi parasites recovered from (A) control MOPC31C and (B)
1.11.1 anti-TPI antibody treated mice after 14 days. Note oocytes
in control worms with pretzel and stretched Mf, whereas uterine
contents in anti-Bm-TPI worms are smaller and potentially
degraded.
(PDF)
Figure S3 In vitro or in vivo exposure to Bm-TPI does
not alter T cell responses. A. In vitro production of IL-4, IL-10
and IFN-c by anti-CD3/anti-CD28 stimulated CD4+ T cells 6
Bm-TPI. B. In vivo transfer of OVA-specific DO11.10 transgenic T
cells with pOVA-pulsed BMDC 6 Bm-TPI. (B) Percentage of
spleen (top) or peritoneal (bottom) CD4+ that are OVA-specific.
C. Ex vivo production of IFN-c and IL-4 by gated peritoneal KJ1-
26+CD4+ cells. Similar results to (B–C) were observed if mice were
primed with OVA protein adsorbed to alum adjuvant rather than
DC (data not shown).
(PDF)
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